Liposomal delivery is a pharmaceutical encapsulation technology that wraps a bioactive compound inside a phospholipid bilayer. This bilayer is structurally identical to cell membranes in the human body. The liposome allows oral supplements to bypass gastric degradation and reach systemic circulation intact — a fundamental difference from standard tablets and powders.
The Moana Natura LipoSone™ system uses sunflower-derived phosphatidylcholine to create these protective shells. Every formulation across the liposomal line (Glutathione, Iron, and Curcumin) relies on the same delivery mechanism, which is why understanding how it works matters for understanding why format determines bioavailability more than raw dose.
The Problem Liposomes Solve: Gastric Degradation
Standard oral supplements face a hostile environment in the digestive tract. Glutathione is a tripeptide — a small protein chain — that stomach acid and digestive enzymes (proteases) break apart before it can be absorbed. Iron tablets are often chelated to minerals, but this chelation can be disrupted by gastric pH and competing nutrients in food. Curcumin is lipophilic — fat-soluble — which means it dissolves poorly in water and remains unabsorbed in the intestinal lumen until it is excreted.
The intestinal epithelium presents a second barrier. A molecule must either be small enough to pass through tight junctions between cells (paracellular absorption), or it must be actively transported by specific carrier proteins. Most supplement actives lack dedicated transporters. The small intestine is where absorption happens, but only if the compound survives stomach acid and has sufficient solubility.
Standard tablets assume oral bioavailability of 10–40% for many compounds. This means 60–90% of the dose is lost to degradation or poor absorption before reaching sufficient plasma concentration to have a biological effect.
How Liposomal Encapsulation Changes the Pathway
A liposomal glutathione molecule is not a free glutathione tripeptide exposed to stomach acid. It is a glutathione tripeptide enclosed within a phospholipid shell. The phospholipid bilayer is impermeable to proteases and resistant to pH changes across a wide physiological range.
Liposomes pass through the stomach largely intact. In the small intestine, the liposomal shell interacts with bile salts and intestinal lipase — natural emulsifiers present in the gut. These agents can destabilise the liposome in a controlled way, releasing the payload at the site of maximum absorption (the proximal small intestine). Alternatively, intact liposomes can merge directly with the apical membrane of intestinal epithelial cells through a mechanism called membrane fusion. This fusion allows the liposomal contents to bypass the need for active transporters — the cell takes up the entire liposome, and the contents are released into the cytoplasm.
The membrane fusion mechanism matters because it is dose-independent. Standard absorption pathways that rely on finite numbers of carrier proteins reach saturation at high doses — additional dose yields diminishing returns. Liposomal fusion does not have this ceiling.
Once the bioactive compound reaches the bloodstream, it enters systemic circulation as an absorbed molecule. Plasma concentration — measured as micromoles per litre — is the metric for bioavailability. Higher plasma concentration at lower dose means higher bioavailability.
Measuring Bioavailability: The RCT Standard
Bioavailability is quantified by comparing plasma concentration curves between a test product and a reference. The reference is typically the standard form (tablet, powder) of the same compound. A randomised controlled trial with human participants establishes this comparison.
The area under the plasma concentration curve (AUC) — the total exposure over time — is the primary bioavailability metric. A higher AUC at the same dose means more of the compound reached systemic circulation.
LipoSone™ Bioavailability Data
| Formulation | Dose | AUC vs. Standard | Comparator |
|---|---|---|---|
| Liposomal Glutathione | 500 mg | 63.62× higher AUC | Standard tablet (same dose) |
| Liposomal Iron | 15 mg | 397.7× higher AUC | Standard iron powder (same dose) |
| Liposomal Iron | 15 mg | 44.4× higher AUC | Iron tablet + vitamin C (optimised standard) |
| Liposomal Curcumin | 250 mg | 46.79× higher AUC | Standard curcumin extract (same dose) |
Liposomal Glutathione
The Liposomal Glutathione RCT followed 20 participants (10 receiving liposomal glutathione, 10 receiving standard tablet glutathione) in a crossover design. Plasma glutathione was measured at baseline, 0.5 hours, 1 hour, 2 hours, 4 hours, and 7 hours post-dose. The AUC was 63.62 times higher for the liposomal form than the standard tablet at the same 500 mg dose.
Liposomal Iron
Liposomal Iron showed AUC 397.7 times higher than a standard iron powder comparator at the same 15 mg dose. When compared to a tablet formulation combined with vitamin C (a known iron absorption enhancer), the liposomal form still achieved 44.4 times higher AUC. This demonstrates that liposomal delivery outperforms even optimised standard formulations.
Liposomal Curcumin
Liposomal Curcumin achieved 46.79 times higher AUC than standard curcumin extract. Peak plasma concentration (Cmax) was reached at 2 hours for the liposomal form — significantly faster than standard formulations, which show delayed and lower peaks due to poor solubility and absorption.
Why Format Matters More Than Dose
A poorly absorbed compound at high dose delivers less systemic exposure than a well-absorbed compound at low dose. Format — the delivery vehicle — is the primary lever for bioavailability, not the amount of active ingredient listed on the label.
Consider the comparison for curcumin:
- Standard curcumin at 1,000 mg: Typical oral bioavailability 10–15% → ~100–150 mg absorbed
- LipoSone™ curcumin at 250 mg: 46.79× higher AUC than standard → substantially higher absorbed amount per mg dose
The absorbed amount — the amount that reaches systemic circulation — is what creates a measurable biological response. Dose listed on the label matters only insofar as the delivery system allows it to be absorbed.
This principle applies across all three LipoSone formulations. The standardised dose is not the “maximum amount to take” — it is the amount calibrated to the liposomal delivery system to achieve the maximum absorption per unit.
LipoSone™: Implementation Details
LipoSone™ uses sunflower-derived phosphatidylcholine (a plant-based phospholipid) to form the bilayer. Sunflower lecithin is non-GMO and soy-free — important because soy phospholipids can cross-react with soy allergies. LipoSone formulations are designed to be hypoallergenic.
Each formulation is manufactured in Germany in a GMP-certified facility. The liposomal suspension is bottled as a liquid (not a powder requiring reconstitution). Liquid liposomes are inherently more stable than powders and do not require additional encapsulation steps.
Daily serving sizes are calibrated to the liposomal payload — the doses at which bioavailability was measured in the respective RCTs:
- Glutathione: 7 mL per day (500 mg reduced L-glutathione)
- Iron: 5 mL per day (15 mg liposomal iron saccharate)
- Curcumin: 7 mL per day (250 mg curcumin)
Every batch undergoes third-party testing in independent European laboratories, confirming identity (the active is present), purity (contaminants below regulatory thresholds), and potency (dose matches the label).
The Liposomal Advantage: Three Problems Solved
Liposomal delivery solves three problems simultaneously:
- Protection from degradation. Glutathione survives the stomach intact. Curcumin solubility is no longer a barrier to absorption.
- Higher absorbed fraction. Bioavailability is not 10–30% — it is substantially higher, measured at 46.79× to 397.7× in published RCTs.
- Lower dose, higher systemic concentration. This reduces pill burden, lowers cost per unit of absorbed bioactive, and reduces the risk of interactions from consuming large tablet volumes.
The tradeoff is manufacturing complexity. A liposomal formulation requires precise control of phospholipid ratios, bilayer size, encapsulation efficiency, and stability over the product shelf life. It cannot be manufactured as a simple tablet press. This is why liposomal supplements cost more than standard tablets at the same listed dose — the format is the value, and the format is expensive to produce at clinical standards.
For compounds that are poorly absorbed in standard form, liposomal delivery is not a luxury. It is the practical ceiling on what oral supplementation can achieve.